Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025

Core Insights - Adlai Nortye Ltd. is set to present two abstracts at the upcoming American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025, in Chicago, showcasing its innovative cancer therapies [1][2]. Group 1: Presentation Details - The first poster presentation is titled "Coordinated stimulation of APC and T cell functions by first-in-class, tri-specific AN8025 for next-generation cancer immunotherapy," scheduled for April 28, 2025 [3]. - The second poster presentation is titled "AN9025, an orally bioavailable pan-RAS(ON) inhibitor with potent, broad-spectrum anti-tumor activity," scheduled for April 29, 2025 [3]. Group 2: Product Information - AN8025 is a proprietary tri-specific antibody fusion protein designed to enhance T cell and antigen-presenting cell functions, with preclinical studies showing robust anti-tumor efficacy [4]. - AN9025 is an oral small molecule pan-RAS(ON) inhibitor targeting a broad spectrum of RAS mutations, demonstrating potent efficacy against various cancers, including pancreatic, lung, and colorectal adenocarcinomas [5]. Group 3: Company Overview - Adlai Nortye is a global clinical-stage biotechnology company focused on developing innovative cancer therapies, with R&D centers in the U.S. and China [6]. - The company is advancing a robust oncology pipeline, including its lead candidate Buparlisib (AN2025), currently in a Phase 3 trial for recurrent or metastatic head and neck squamous cell cancer [6].